Bioventus Inc.

Bioventus Inc. is a U.S.-based medical device company focused on helping patients recover from musculoskeletal conditions and pain through products used in orthopedics, spine, neurosurgery, and related care settings. Its portfolio is organized around three businesses: Pain Treatments & PRP, Surgical Solutions, and Restorative Therapies. The company sells clinically oriented products such as hyaluronic acid injections for knee osteoarthritis, peripheral nerve stimulation systems, ultrasonic bone resection tools, bone graft substitutes, and ultrasound-based fracture healing devices. Bioventus operates through U.S. and International reporting segments and uses a mix of direct sales, distributors, and market-access channels to reach physicians, hospitals, IDNs, GPOs, and specialty care providers. In late 2024 it divested its Advanced Rehabilitation Business, signaling a sharper focus on core musculoskeletal and surgical franchises.

17,8 %

68,3 %

4,0 %

−0,9 %

1.70

1.19

— Bioventus Inc.
%
Pain Treatments & PRP40% Intra-articular hyaluronic acid injections, PRP systems, and peripheral nerve stimulation products used to relieve pain and support recovery.
Surgical Solutions35% Ultrasonic bone resection tools and bone graft substitutes used in spine, neurosurgery, and orthopedic procedures.
Restorative Therapies20% Bone-healing products such as EXOGEN that use low-intensity ultrasound to support fracture repair.
International and Distributor Sales5% Non-U.S. sales channels and distributor-led commercialization across selected markets and procedures.

Bioventus sells primarily to physicians and healthcare providers who treat orthopedic and musculoskeletal conditions,...

  • Orthopedic physicians and surgeonsprimary

    Buy HA injections, PRP, bone graft substitutes, and fracture-healing products to treat osteoarthritis, fractures, and other musculoskeletal conditions.

  • Spine and neurosurgery hospitalsprimary

    Buy ultrasonic bone resection systems and related surgical products for precision cutting in spine, brain, and other procedures.

  • Pain management specialistssecondary

    Buy peripheral nerve stimulation products and related pain-treatment solutions to address acute and chronic pain.

  • Healthcare purchasing organizationssecondary

    IDNs, GPOs, and large accounts influence which products are approved, standardized, and reimbursed across care networks.

  • International distributorssecondary

    Purchase and resell products in selected non-U.S. markets where Bioventus relies on indirect commercialization.

Bioventus reports its business through U.S. and International segments, with the U.S. accounting for 88% of net sales...

  • •U.S. segment is the core market and represented 88% of 2025 net sales
  • •International segment represented 12% of 2025 net sales
  • •U.S. sales are supported by direct sales and market-access teams
  • •International sales rely more on distributors and indirect channels
  • •Supplier footprint includes Japan, Switzerland, Sweden, and the U.S.
  • •Foreign-currency exposure arises from cross-border cash and intercompany balances

Bioventus is concentrating on its core musculoskeletal and surgical franchises after divesting the non-core Advanced...

01
Defend and grow core pain, bone graft, and fracture-care franchisesshort-term

These products generate the majority of sales and fund investment in newer platforms.

02
Expand Ultrasonics and international commercializationmedium-term

These areas provide additional growth runway beyond the mature U.S. core.

03
Build emerging PNS and PRP platformsmedium-term

These offerings can diversify the portfolio and deepen physician relationships if adoption scales.

Bioventus faces typical medical-device risks tied to regulation, reimbursement, and hospital purchasing power, all of...

high

Healthcare purchasing consolidation and reimbursement pressure

Hospitals, GPOs, IDNs, and payers can demand lower prices, rebates, or vendor exclusion, which can compress margins and reduce access.

Scope
Core U.S. commercial business
Materiality
high
high

Regulatory and product compliance risk

Medical devices are subject to extensive FDA and foreign oversight across design, labeling, clinical testing, and marketing; failures can delay launches or trigger recalls.

Scope
All product lines
Materiality
high
high

Supply-chain and third-party manufacturing dependence

Certain products are sourced from suppliers in Japan, Switzerland, Sweden, and the U.S., so disruptions or quality issues can affect sales and gross margin.

Scope
Surgical Solutions and Restorative Therapies
Materiality
high
high

Debt covenant and liquidity constraints

The 2025 Credit Agreement includes leverage and interest-coverage covenants that could restrict borrowing and strategic actions if performance weakens.

Scope
Corporate finance
Materiality
high
medium

Foreign trade and sourcing restrictions

Restrictions on foreign-manufactured equipment or supplies, including China-related import rules, could limit sourcing options or raise costs.

Scope
Global supply chain
Materiality
medium
Point-in-time revenue recognition
Affects quarterly revenue comparability and cutoff risk
Variable consideration and rebates
Affects reported revenue and gross margin
Contingent consideration
Affects financing cash flow and non-operating expense
Tax receivable agreement
Affects cash taxes and balance-sheet liabilities
Inventory and product-related intangibles
Affects cost of sales and asset carrying values

Axogen, Inc.

AXGN · Electromedical & Electrotherapeutic Apparatus

Enovis CORP

ENOV · Orthopedic, Prosthetic & Surgical Appliances & Supplies

GLOBUS MEDICAL INC

GMED · Surgical & Medical Instruments & Apparatus

BIOGEN INC.

BIIB · Biological Products, (No Diagnostic Substances)

PROVECTUS BIOPHARMACEUTICALS, INC.

PVCT · Pharmaceutical Preparations

SI-BONE, Inc.

SIBN · Surgical & Medical Instruments & Apparatus

: 11/08/2026